Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
4.380
+0.590 (15.57%)
At close: Jun 4, 2026, 4:00 PM EDT
4.395
+0.015 (0.34%)
Pre-market: Jun 5, 2026, 7:46 AM EDT
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Iovance Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $8.80. The average 1-year stock price forecast is 100.91% higher than the current stock price, while the lowest is $4.00 (-8.68%) and the highest is $14 (+219.63%).
Price Target: $8.80 (+100.91%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 4 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $9 | Buy | Reiterates | $9 | +105.48% | Jun 1, 2026 |
| Barclays | Barclays | Buy Reiterates $11 | Buy | Reiterates | $11 | +151.14% | May 8, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $14 | Buy | Reiterates | $14 | +219.63% | May 8, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $5 | Buy | Maintains | $5 | +14.16% | May 7, 2026 |
Unknown Analyst Mizuho Securities No rating | Mizuho Securities | Buy Maintains $10 | Buy | Maintains | $10 | +128.31% | Mar 30, 2026 |
Financial Forecast
Revenue This Year
361.24M
from 263.50M
Increased by 37.09%
Revenue Next Year
522.78M
from 361.24M
Increased by 44.72%
EPS This Year
-0.55
from -1.09
EPS Next Year
-0.32
from -0.55
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 369.8M | ||
| Avg | 361.2M | ||
| Low | 352.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 40.3% | ||
| Avg | 37.1% | ||
| Low | 33.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.42 | ||
| Avg | -0.55 | ||
| Low | -0.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.